おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Variantyx
company
About
Variantyx offers a comprehensive set of advanced genomic diagnostic products and services with a focus on whole genome sequencing.
- 101 - 250
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Genetics,Health Care,Health Diagnostics,Information Technology,Life Science,Personal Health
- Founded date
- Jan 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditional step-wise, reiterative genetic testing.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$40M
Variantyx has raised a total of
$40M
in funding over 2 rounds. Their latest funding was raised on
Oct 18, 2022 from a Debt Financing round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 18, 2022 | Debt Financing | $20M | 1 |
Kreos Capital
|
— | Detail |
| Mar 15, 2021 | Series C | $20M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Variantyx is funded by 2 investors.
Kreos Capital
and Global health sciences venture fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kreos Capital
|
Yes | Debt Financing |
|
|
Yes | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
